Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)
China · Delayed Price · Currency is CNY 10.53
+0.09 (0.86%)
Feb 3, 2026, 2:55 PM CST
SHA:600420 Revenue
In the year 2025, Shanghai Shyndec Pharmaceutical had annual revenue of 9.36B CNY, down -14.40%. Shanghai Shyndec Pharmaceutical had revenue of 2.44B in the quarter ending December 31, 2025, with 4.20% growth.
Revenue
9.36B
Revenue Growth
-14.40%
P/S Ratio
1.50
Revenue / Employee
816.17K
Employees
11,472
Market Cap
14.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.36B | -1.57B | -14.40% |
| Dec 31, 2024 | 10.94B | -1.13B | -9.38% |
| Dec 31, 2023 | 12.07B | -889.39M | -6.86% |
| Dec 31, 2022 | 12.96B | -985.63M | -7.07% |
| Dec 31, 2021 | 13.94B | 1.39B | 11.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Medicine | 8.96B |
| Guobang Pharma | 5.94B |
| Zhejiang Jingxin Pharmaceutical | 4.00B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |
| Porton Pharma Solutions | 3.43B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.72B |
| Shanghai Haoyuan Chemexpress | 2.71B |
| Beijing Aosaikang Pharmaceutical | 1.83B |